<DOC>
	<DOCNO>NCT00000596</DOCNO>
	<brief_summary>To determine effect cyclophosphamide compare prednisone , dapsone , high-dose intermittent 'pulse ' therapy methylprednisolone patient idiopathic pulmonary fibrosis . Also , evaluate use intermittent , short-term , high-dose intravenous corticosteroid patient sarcoidosis . There actually four separate clinical trial .</brief_summary>
	<brief_title>Diffuse Fibrotic Lung Disease</brief_title>
	<detailed_description>BACKGROUND : The fibrotic lung disease represent 15 20 percent non-infectious disorder lung . Idiopathic pulmonary fibrosis , one 10 general group fibrotic lung disorder , chronic devastate illness result death within average 4 5 year onset symptom . Although 5 10 percent patient respond corticosteroid , know treatment remainder . Sarcoidosis , generalize disorder characterize epithelioid cell granuloma formation affect organ , especially lung lymphoid tissue , clinical course varies considerably patient patient , case , resolve spontaneously . In case , intermittent pneumonitis develops , may result permanent loss lung function . Large intermittent dos corticosteroid might superior conventional high-dose corticosteroid patient pulmonary sarcoidosis resolve spontaneously . DESIGN NARRATIVE : In randomize , non-blind cyclophosphamide versus prednisone trial , 25 50 patient idiopathic pulmonary fibrosis assign treatment prednisone cyclophosphamide . At end 52 week drug therapy , group treat use conventional medical therapy . In non-randomized dapsone trial , 10 fibrotic patient treat dapsone prednisone one year . In double-blind , randomize methylprednisolone trial , 25 50 patient give low-dose methylprednisolone , , addition , patient randomize either high-dose methylprednisolone treatment placebo weekly interval one year . In randomized , double-blind , high-dose corticosteroid trial , 25 50 patient pulmonary sarcoidosis give short intense course high-dose methylprednisolone placebo 6 week . The study completion date list record infer last publication list Citations section study record .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
</DOC>